Soluble CD23 Expression in Asthma Patients Treated With OMA

Summary

This study involves a FDA approved drug, Omalizumab, used in the treatment of moderate to severe allergic asthma that cannot be controlled by standard treatment. It works on IgE to control the allergic reaction. We are looking at the effects on non-allergic asthma. We hope to prove that Omalizumab will have the same effect on non-allergic asthmatics as it does allergic asthmatics.

Timeline

Start

2004-11

Primary completion

2007-10

Completion

2007-10

Drugs

Indications